Author: CSANZ Admin

A 38 year-old develops left arm and wrist pain while riding his bicycle. ECG is shown below. A coronary angiogram is planned. What does the ECG show?

Figure 1:

provided by Alex Voskoboinik July 2022

The Answer: Left arm – Right arm lead reversal

The emergency department doctors were concerned about T-wave inversion in lead I and aVL and diagnosed coronary ischaemia. In fact, this is a classic case of Left arm – right arm lead reversal. In this situation, Einthoven’s triangle flips 180 ̊horizontally so Lead I is inverted, aVL and aVRswitch places, as do leads II and III. The key to diagnosing lead reversals is that P waves, QRS complexes and T-waves are all inverted. In this case the p wave is negative in lead I which is not characteristic of sinus rhythm. Similarly in aVR, the p wave is positive which is not characteristic of sinus rhythm. A sinus p wave should usually be positive in all leads except aVR and is biphasic (pos/neg) in lead V1. Left arm – right arm lead reversal may appear similar to dextrocardia, however as opposed to dextrocardia there is normal precordial R wave progression in this case. This patient did not proceed to an angiogram.

Our recent paper,  ‘Prevalence of Coronary Artery Anomalies in Young and Middle-Aged Sudden Cardiac Death Victims’ examines the rate of coronary artery anomalies in the largest population of sudden cardiac death patients examined in Australia. From a population of approximately 1500 Victorians aged 1-50 years who experienced sudden cardiac arrest, over 700 underwent a comprehensive autopsy. A 1% rate of anomalies of coronary artery anatomy was identified, which is consistent with reported rates in angiographic, CT and other post-mortem series – this is reassuring that our dataset was representative of general findings.

However, within this 1% prevalence of coronary artery anomalies, not a single person had experienced their sudden cardiac arrest due to their coronary anomaly. All patients had clear alternative reasons for their death identified, such as another coronary artery occluded with acute thrombus, histological evidence of acute myocardial infarction or a ruptured thoracic aortic dissection.

This study is important, because it challenges earlier assumptions that coronary artery anomalies are a major cause of young sudden cardiac death. Early investigations into sudden cardiac death reported that coronary artery anomalies caused up to one-third of young sudden cardiac deaths. These studies included only a few dozen patients and were published several decades ago. However, citing these studies, both US and European guidelines have traditionally restricted participation in elite sport for patients with coronary anomalies.

Our dataset is not only the largest published in Australia, but also one of the largest in the world and our findings accord with contemporary figures from other major sudden cardiac death research teams. We hope that our data will prompt a re-appraisal and further investigations into the true role of coronary artery anomalies in young sudden cardiac death.

Summary by Dr Elizabeth Paratz

Available now as a preprint in The American Journal of Cardiology
Link to full article here:

Summary by Kevin Rajakariar 15 June 2022.

Authors: Kevin Rajakariar, Nick Andrianopoulos, Daniel Gayed, Danlu Liang, Brendan Backhouse, Andrew E Ajani, Stephen J Duffy, Angela Brennan, Louise Roberts, Christopher M Reid, Ernesto Oqueli, David Clark, Melanie Freeman

The use of thrombectomy during primary percutaneous coronary intervention has been a controversial topic, with large randomised controlled trials demonstrating conflicting results. While more recent randomised studies demonstrate no clear benefit in the use of routine thrombectomy during primary PCI, there are minimal real-world studies utilising thrombectomy in selected higher risk patients. These patients may have an increased thrombus burden, higher lesion complexity, no-reflow phenomenon, and evidence of cardiogenic shock. In addition, there have been significant concerns of the peri-procedural stroke risk associated with the use of thrombectomy, with further conflicting results between studies.

Our study analysed 6,270 consecutive patients between 2007 and 2018 undergoing primary PCI for STEMI, of which 26% underwent thrombectomy. While thrombus aspiration was most likely to be used in complex lesions with no coronary perfusion, there was no significant difference in post-procedural coronary flow, stroke, or mortality. Although there was a reduction in 30-day major adverse cardiovascular and cerebrovascular events, this was not associated with a reduction in long-term mortality. However, thrombectomy was most likely to be used in sicker patients and it is unclear whether this subgroup of patients would have inferior outcomes if thrombectomy was not performed.

Available online now on the Internal Medicine Journal accepted articles page: https://onlinelibrary.wiley.com/doi/epdf/10.1111/imj.15828

Surgical cryoablation should be considered in patients with mitral valve prolapse (MVP) undergoing mitral valve surgery who have malignant ventricular arrhythmias or high ventricular ectopy load, as recommended in our article now published online in Heart, Lung and Circulation [1].

Mitral valve prolapse is a relatively common condition with a community incidence of about 2.4% [2]. While it generally has good prognosis, a small subset of patients suffer from malignant arrhythmia and sudden cardiac death. Out of 650 autopsies in young adults who died suddenly, 7% were due to MVP [3].

Ventricular ectopics are common in MVP. In a series of 595 consecutive patients, 43% had >5% and one third had moderate or severe nonsustained ventricular tachycardia [4]. These ectopics mainly arise from one or both papillary muscles and may act as triggers for malignant ventricular arrhythmias. Radiofrequency (RF) ablation is considered for malignant arrhythmia or in MVP patients in whom high ventricular ectopy load causes LV dysfunction. RF ablation of the papillary muscles has a modest success rate and high arrhythmia recurrence rate. Mitral valve surgery by itself does not prevent malignant ventricular arrhythmia.

In Heart, Lung and Circulation, we reported 3 cases of MVP and malignant ventricular arrhythmia who not only had mitral valve surgery but also underwent cryoablation of the papillary muscles at the time of surgery.

Two patients had moderate and one severe mitral regurgitation. All had received shocks from their implanted cardioverter defibrillators (ICDs) and were not controlled with drug therapy. At surgery, encircling cryolesions were placed at the base of the papillary muscles which also targets distal arborisation of the Purkinje system. During a follow up of 3–11 years, all three patients have remained free of both malignant arrhythmia and ICD shocks. Cryoablation of papillary muscles had no detrimental effect on mitral valve function for any patient.

While we had not performed cardiac MRI in any of our patients, we would recommend it to assess areas of myocardial fibrosis which could be targeted by cryoablation. Further, wherever possible, we would now consider mitral valve repair rather than replacement.

References

1. Vohra J, Morton JB, Morgan J, Tatoulis J. Cryoablation of papillary muscles at surgery for malignant ventricular arrhythmias due to mitral valve prolapse. Heart Lung Circ 2022. Link to online article: Cryoablation of Papillary Muscles at Surgery for Malignant Ventricular Arrhythmias Due to Mitral Valve Prolapse – Heart, Lung and Circulation (heartlungcirc.org).
2. Levine RA, Hagége AA, Judge DP, Padala M, Dal-Bianco JP, Aikawa E, et al.; Leducq Mitral Transatlantic Network. Mitral valve disease—morphology and mechanisms. Nat Rev Cardiol 2015;12:689–710.
3. Basso C, Perazzolo Marra M, Rizzo S, De Lazaari M, Giorgi B, Cipriani A, et al. Arrhythmic mitral valve prolapse and sudden cardiac death. Circulation 2015;132:556–66.
4. Essayagh B, Sabbag A, Antoine C, Benfari G, Yang LT, Maalouf J et al. Presentation and outcome of arrhythmic mitral valve prolapse. J Am Coll Cardiol 2020;76:637-49.

By Jitendra Vohra, Joseph B Morton, John Morgan and James Tatoulis

A 48 year-old male presents with 3 months of exertional dyspnoea.

He takes candesartan 8 mg daily and atenolol 50 mg daily for hypertension. ECG is shown above (Fig 1).

What is the most likely diagnosis?

This patient was originally diagnosed with sinus tachycardia at 100 bpm.

In fact this patient has a focal atrial tachycardia originating from the right upper pulmonary vein (ECG following ablation shown in Figure 3). Atrial flutter or atrial tachycardia with 2:1 conduction (the start of the ECG) are often misdiagnosed as sinus tachycardia. There are two important signs that should make one suspicious that this is not sinus rhythm. Firstly, the presence of a long apparent PR interval would be unusual for sinus tachycardia in a young patient whereby elevated sympathetic tone would ensure more slick conduction down the AV node. Secondly, ‘funny’ appearance of T-waves should make one suspicious that there are P waves buried within them. Looking at all leads, particularly V1 (Figure 2) and mapping them out is instructive.

Stem: A 29 year-old male presents with a 2 month history of frequent palpitations. His initial ECG is shown in Figure A. Bedside TTE shows mild-moderate global LV dysfunction. What are the differential diagnoses?

Answer: This is a regular wide complex tachycardia with left bundle branch block morphology (QRS width ~ 125ms). Differential diagnoses for regular wide complex tachycardia (QRS > 120 ms) in general include VT, SVT with aberrancy (any regular SVT – inc. atrial tachycardia, AVNRT, AVRT, atrial flutter, sinus tachycardia), and pre-excited tachycardia. The typical LBBB morphology suggests that the ventricle is being activated from the region of the right bundle. Hence, specific diagnoses to consider given the morphology include SVT with LBBB aberrancy (or fixed LBBB), bundle branch reentrant VT, idiopathic moderator band VT and atriofascicular antidromic tachycardia.

Stem (continued): Adenosine was given with no effect suggesting this was less likely to be a re-entrant SVT involving the AV node (ie. AVNRT, AVRT). He was subsequently given metoprolol and amiodarone – ECGs post are shown (Figure B and C). Does this help with the diagnosis?

Answer: These ECGs rule in VT – there is clear cut AV dissociation (sinus p waves regularly marching through). In Figure C, there is some irregularity suggesting an automatic (rather than re-entrant) mechanism. VT continued despite cardioversion and amiodarone. Thus the patient has incessant VT causing a tachycardia mediated cardiomyopathy. Catheter ablation was performed with the focal VT successfully ablated at the moderator band (adjacent to the exit of the right bundle – hence the typical LBBB morphology). LV function returned to normal after 2 months.

Want to discuss these further – Ask a Question of A/Prof Alex Voskoboinik or upload your own Images for discussion.

Uploaded files:

Prof Kazuaki Negishi, 24 May 2022

Cardio-oncology is a rapidly emerging speciality globally. Cardio-oncology is dedicated to the prevention, identification, and treatment of cardiovascular complications in cancer patients as well as in long-term survivors. This is pertinent as cancer treatments are more complex than ever and cancer survivorship is rapidly increasing. Notably, Australia has one of the best cancer survivor rates globally.

An article published in the Internal Medicine Journal, led by Professor Kazuaki Negishi, senior author and of University of Sydney and Nepean Hospital assessed the status of cardio-oncology services in Australia through an online multi-disciplinary survey. There were 118 responses analysed with 70% reporting no dedicated cardio-oncology services existed at their institution, with insufficient funding being the main reason. Most respondents were oncologists (35%), followed by cardiologist (31%), haematologist (18%) and radiation oncologists (14%). The vast majority of respondents agreed or strongly agreed (86%) cardio-oncology is an important sub-speciality. Cancer specialists estimated 15% of their patients did not receive optimal cancer care due to cardiotoxicity or a history of cardiovascular disease. Additionally, 50% of cancer specialists were neutral to very unconfident in identifying cardiotoxicity. In regard to cardio-oncology education, nearly all respondent supported increased cardio-oncology session at national society meetings (88%) and the creation of national cardio-oncology guidelines (97%).

The results of this Australian first survey demonstrate “the overwhelming support for Australian cardio-oncology guidelines and an increased presence at national society meetings suggest there is a sizable appetite for the growth of cardio-oncology services in Australia.” Hopefully, these findings can be used for an evidence base for further funding of cardio-oncology services in Australia.

In conclusion, the authors suggest “a multi-disciplinary team funding model following existing templates in oncology may be a pathway forward. Our findings indicate that there is a strong support for further cardio-oncology education, guidelines and services nationally.”

You can find the full article here: https://onlinelibrary.wiley.com/doi/10.1111/imj.15682